microRNA‑93, upregulated in serum of nasopharyngeal carcinoma patients, promotes tumor cell proliferation by targeting PDCD4

Sun,Jie; Yong,Jun; Zhang,Hua

doi:10.3892/etm.2020.8520

microRNA‑93, upregulated in serum of nasopharyngeal carcinoma patients, promotes tumor cell proliferation by targeting PDCD4

Authors:
- Jie Sun
- Jun Yong
- Hua Zhang
View Affiliations

Affiliations: Department of Otolaryngology-Head and Neck Surgery, The Eighth Affiliated Hospital of Sun Yat-Senl University, Shenzhen, Guangdong 518000, P.R. China, Department of Otolaryngology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China
Published online on: February 11, 2020 https://doi.org/10.3892/etm.2020.8520
Pages: 2579-2587
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Deregulation of microRNAs (miRs) has been demonstrated to contribute to the development and malignant progression of nasopharyngeal carcinoma (NPC). Recently, miR‑93 was reported to be significantly upregulated in NPC tissues and cell lines, and promote the proliferation, migration and invasion of NPC cells in vitro, as well as tumor growth in vivo. However, whether there is any clinical value of serum miR‑93 expression in NPC still remains unclear. Therefore, the present study aimed to explore the clinical significance of serum miR‑93 expression in NPC. A total of 85 serum samples from NPC patients and 30 from healthy controls were collected. Reverse transcription‑quantitative polymerase chain reaction data demonstrated that the serum expression of miR‑93 was significantly increased in NPC patients, when compared with those in healthy controls. Following receiving chemo‑radiotherapy, the serum miR‑93 levels were significantly decreased in NPC patients. Furthermore, the increased serum levels of miR‑93 were significantly associated with advanced grade, clinical stage, lymph node metastasis, as well as worse 5‑year overall survival of NPC patients. Furthermore, the serum miR‑93 expression was demonstrated to be an independent factor for predicating the prognosis of NPC. In vitro experiments demonstrated that knockdown of miR‑93 caused a decrease in NPC cell proliferation, whereas overexpression of miR‑93 promoted NPC cell proliferation. PDCD4 was then identified as a direct target of miR‑93 in NPC cells. Overexpression of PDCD4 significantly eliminated the promoting effects of miR‑93 overexpression on NPC cell proliferation. Taken together, these findings suggest that the serum miR‑93 expression could be used as a predicator for the clinical outcome of NPC patients, and suggest that miR‑93 may also become a potential therapeutic target for NPC treatment.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI View Article : Google Scholar
2	Wei WI and Sham JS: Nasopharyngeal carcinoma. Lancet. 365:2041–2054. 2005.PubMed/NCBI View Article : Google Scholar
3	Yip TT, Ngan RK, Fong AH and Law SC: Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma. Oral Oncol. 50:527–538. 2014.PubMed/NCBI View Article : Google Scholar
4	Sze H, Blanchard P, Ng WT, Pignon JP and Lee AW: Chemotherapy for nasopharyngeal carcinoma-current recommendation and controversies. Hematol Oncol Clin North Am. 29:1107–1122. 2015.PubMed/NCBI View Article : Google Scholar
5	Xiao L, Xiao T, Wang ZM, Cho WC and Xiao ZQ: Biomarker discovery of nasopharyngeal carcinoma by proteomics. Expert Rev Proteomics. 11:215–225. 2014.PubMed/NCBI View Article : Google Scholar
6	Lee AW, Lin JC and Ng WT: Current management of nasopharyngeal cancer. Semin Radiat Oncol. 22:233–244. 2012.PubMed/NCBI View Article : Google Scholar
7	Zeng X, Xiang J, Wu M, Xiong W, Tang H, Deng M, Li X, Liao Q, Su B, Luo Z, et al: Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One. 7(e46367)2012.PubMed/NCBI View Article : Google Scholar
8	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004.PubMed/NCBI View Article : Google Scholar
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI View Article : Google Scholar
10	Chen HC, Chen GH, Chen YH, Liao WL, Liu CY, Chang KP, Chang YS and Chen SJ: MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 100:1002–1011. 2009.PubMed/NCBI View Article : Google Scholar
11	Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, et al: MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 71:2381–2391. 2011.PubMed/NCBI View Article : Google Scholar
12	Ye JJ and Cao J: MicroRNAs in colorectal cancer as markers and targets: Recent advances. World J Gastroenterol. 20:4288–4299. 2014.PubMed/NCBI View Article : Google Scholar
13	Yu BL, Peng XH, Zhao FP, Liu X, Lu J, Wang L, Li G, Chen HH and Li XP: MicroRNA-378 functions as an onco-miR in nasopharyngeal carcinoma by repressing TOB2 expression. Int J Oncol. 44:1215–1222. 2014.PubMed/NCBI View Article : Google Scholar
14	Qu MH, Han C, Srivastava AK, Cui T, Zou N, Gao ZQ and Wang QE: miR-93 promotes TGF-β-induced epithelial-to-mesenchymal transition through downregulation of NEDD4L in lung cancer cells. Tumour Biol. 37:5645–5651. 2016.PubMed/NCBI View Article : Google Scholar
15	Fabbri E, Brognara E, Montagner G, Ghimenton C, Eccher A, Cantù C, Khalil S, Bezzerri V, Provezza L, Bianchi N, et al: Regulation of IL-8 gene expression in gliomas by microRNA miR-93. BMC Cancer. 15(661)2015.PubMed/NCBI View Article : Google Scholar
16	Ansari MH, Irani S, Edalat H, Amin R and Mohammadi Roushandeh A: Deregulation of miR-93 and miR-143 in human esophageal cancer. Tumour Biol. 37:3097–3103. 2016.PubMed/NCBI View Article : Google Scholar
17	Kawano M, Tanaka K, Itonaga I, Ikeda S, Iwasaki T and Tsumura H: microRNA-93 promotes cell proliferation via targeting of PTEN in Osteosarcoma cells. J Exp Clin Cancer Res. 34(76)2015.PubMed/NCBI View Article : Google Scholar
18	Chen L, Jiang M, Yuan W and Tang H: Prognostic value of miR-93 overexpression in resectable gastric adenocarcinomas. Acta Gastroenterol Belg. 75:22–27. 2012.PubMed/NCBI
19	Xu YF, Mao YP, Li YQ, Ren XY, He QM, Tang XR, Sun Y, Liu N and Ma J: MicroRNA-93 promotes cell growth and invasion in nasopharyngeal carcinoma by targeting disabled homolog-2. Cancer Lett. 363:146–155. 2015.PubMed/NCBI View Article : Google Scholar
20	Lyu X, Fang W, Cai L, Zheng H, Ye Y, Zhang L, Li J, Peng H, Cho WC, Wang E, et al: TGFβR2 is a major target of miR-93 in nasopharyngeal carcinoma aggressiveness. Mol Cancer. 13(51)2014.PubMed/NCBI View Article : Google Scholar
21	Li Y, Ou X and Hu C: Validation and suggestion of eighth T classifications of the UICC/AJCC staging system for nasopharyngeal carcinoma patients: A retrospective analysis. Jpn J Clin Oncol. 48:927–933. 2018.PubMed/NCBI View Article : Google Scholar
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
23	Tan G, Liu Q, Tang X, Kang T, Li Y, Lu J, Zhao X and Tang F: Diagnostic values of serum cathepsin B and D in patients with nasopharyngeal carcinoma. BMC Cancer. 16(241)2016.PubMed/NCBI View Article : Google Scholar
24	Mao Y, Wu S, Zhao R and Deng Q: MiR-205 promotes proliferation, migration and invasion of nasopharyngeal carcinoma cells by activation of AKT signalling. J Int Med Res. 44:231–240. 2016.PubMed/NCBI View Article : Google Scholar
25	Chen X, Shi J, Zhong J, Huang Z, Luo X, Huang Y, Feng S, Shao J and Liu D: miR-1, regulated by LMP1, suppresses tumour growth and metastasis by targeting K-ras in nasopharyngeal carcinoma. Int J Exp Pathol. 96:427–432. 2015.PubMed/NCBI View Article : Google Scholar
26	Yu Q, Zhang F, Du Z and Xiang Y: Up-regulation of serum miR-744 predicts poor prognosis in patients with nasopharyngeal carcinoma. Int J Clin Exp Med. 8:13296–13302. 2015.PubMed/NCBI
27	Li G, Ren S, Su Z, Liu C, Deng T, Huang D, Tian Y, Qiu Y and Liu Y: Increased expression of miR-93 is associated with poor prognosis in head and neck squamous cell carcinoma. Tumour Biol. 36:3949–3956. 2015.PubMed/NCBI View Article : Google Scholar
28	Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, Wistuba II, Ji L, Roth JA, Minna JD and Pertsemlidis A: miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res. 7:1234–1243. 2009.PubMed/NCBI View Article : Google Scholar
29	Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW, Yee AJ, Ang LC, He C, Shan SW and Yang BB: MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene. 30:806–821. 2011.PubMed/NCBI View Article : Google Scholar
30	Fang L, Du WW, Yang W, Rutnam ZJ, Peng C, Li H, O'Malley YQ, Askeland RW, Sugg S, Liu M, et al: MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle. 11:4352–4365. 2012.PubMed/NCBI View Article : Google Scholar
31	Xu D, He XX, Chang Y, Sun SZ, Xu CR and Lin JS: Downregulation of MiR-93 expression reduces cell proliferation and clonogenicity of HepG2 cells. Hepatogastroenterology. 59:2367–2373. 2012.PubMed/NCBI View Article : Google Scholar
32	Xiao ZG, Deng ZS, Zhang YD, Zhang Y and Huang ZC: Clinical significance of microRNA-93 downregulation in human colon cancer. Eur J Gastroenterol Hepatol. 25:296–301. 2013.PubMed/NCBI View Article : Google Scholar
33	Yu XF, Zou J, Bao ZJ and Dong J: miR-93 suppresses proliferation and colony formation of human colon cancer stem cells. World J Gastroenterol. 17:4711–4717. 2011.PubMed/NCBI View Article : Google Scholar
34	Tang Q, Zou Z, Zou C, Zhang Q, Huang R, Guan X, Li Q, Han Z, Wang D, Wei H, et al: MicroRNA-93 suppress colorectal cancer development via Wnt/β-catenin pathway downregulating. Tumour Biol. 36:1701–1710. 2015.PubMed/NCBI View Article : Google Scholar
35	Yang IP, Tsai HL, Hou MF, Chen KC, Tsai PC, Huang SW, Chou WW, Wang JY and Juo SH: MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle. Carcinogenesis. 33:1522–1530. 2012.PubMed/NCBI View Article : Google Scholar
36	Zhen Y, Liu Z, Yang H, Yu X, Wu Q, Hua S, Long X, Jiang Q, Song Y, Cheng C, et al: Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. Cell Death Dis. 4(e872)2013.PubMed/NCBI View Article : Google Scholar
37	Zhen Y, Fang W, Zhao M, Luo R, Liu Y, Fu Q, Chen Y, Cheng C, Zhang Y and Liu Z: miR-374a-CCND1-pPI3K/AKT-c-JUN feedback loop modulated by PDCD4 suppresses cell growth, metastasis, and sensitizes nasopharyngeal carcinoma to cisplatin. Oncogene. 36:275–285. 2017.PubMed/NCBI View Article : Google Scholar